Beta Bionics, Inc. reported $119M of revenue over the trailing twelve months, +53% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $119M (to Q2 2026). Net income: −$73M, trailing twelve months to Q2 2026. Free cash flow: −$61M, trailing twelve months to Q2 2026. Operating margin: −70%, trailing twelve months to Q2 2026.

BBNXBeta Bionics, Inc.

Healthcare

$17.44-21% 1Y

$17.44

$8.8652 weeks$31.99

BBNX as reported

Beta Bionics, Inc. reported $119M of revenue over the trailing twelve months, +53% on the year before. 9 reported series are charted on this page, each one as filed.

$119M

Revenue, trailing twelve months · to Q2 2026 · +53% against the twelve months before

Net income: −$73M
Net income · −0.54% year on year · trailing twelve months to Q2 2026
Free cash flow: −$61M
Free cash flow · −1.0% year on year · trailing twelve months to Q2 2026
Operating margin: −70%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BBNX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$119M	+53%	Q2 2026
Net income	−$73M	−0.54%	Q2 2026
EPS	−$1.64	−70%	Q2 2026
Gross margin	58%	n/a	Q2 2026
Operating margin	−70%	n/a	Q2 2026
Net margin	−62%	n/a	Q2 2026
ROE	−26%	n/a	Q2 2026
ROA	−23%	n/a	Q2 2026
Free cash flow	−$61M	−1.0%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.